Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

194,095 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Comparative effectiveness of metformin monotherapy in extended release and immediate release formulations for the treatment of type 2 diabetes in treatment-naïve Chinese patients: Analysis of results from the CONSENT trial.
Ji L, Liu J, Yang J, Li Y, Liang L, Zhu D, Li Q, Ma T, Xu H, Yang Y, Zeng J, Feng B, Qu S, Li Y, Ma L, Lin S, Wang J, Li W, Song W, Li X, Luo Y, Xi S, Lin M, Liu Y, Liang Z. Ji L, et al. Among authors: liu j, liu y. Diabetes Obes Metab. 2018 Apr;20(4):1006-1013. doi: 10.1111/dom.13190. Epub 2018 Jan 22. Diabetes Obes Metab. 2018. PMID: 29227571 Clinical Trial.
A randomized, open-label, multicentre, parallel-controlled study comparing the efficacy and safety of biphasic insulin aspart 30 plus metformin with biphasic insulin aspart 30 monotherapy for type 2 diabetes patients inadequately controlled with oral antidiabetic drugs: The merit study.
Guo L, Chen L, Chang B, Yang L, Liu Y, Feng B. Guo L, et al. Among authors: liu y. Diabetes Obes Metab. 2018 Dec;20(12):2740-2747. doi: 10.1111/dom.13454. Epub 2018 Aug 2. Diabetes Obes Metab. 2018. PMID: 29961975 Clinical Trial.
Subject-driven titration of biphasic insulin aspart 30 twice daily is non-inferior to investigator-driven titration in Chinese patients with type 2 diabetes inadequately controlled with premixed human insulin: A randomized, open-label, parallel-group, multicenter trial.
Yang W, Zhu L, Meng B, Liu Y, Wang W, Ye S, Sun L, Miao H, Guo L, Wang Z, Lv X, Li Q, Ji Q, Zhao W, Yang G. Yang W, et al. Among authors: liu y. J Diabetes Investig. 2016 Jan;7(1):85-93. doi: 10.1111/jdi.12364. Epub 2015 May 25. J Diabetes Investig. 2016. PMID: 26816605 Free PMC article. Clinical Trial.
[Efficacy and safety of alogliptin in treatment of type 2 diabetes mellitus: a multicenter, randomized, double-blind, placebo-controlled phase III clinical trial in mainland China].
Pan C, Li W, Zeng J, Li C, Yang J, Ji Q, Lu J, Lyu X, Li X, Qu S, Xu X, Xue Y, Li L, Jiang Z, Zheng B, Bu R, Han P, Liu Y, Liu J, Peng Y, Liu X, Liu Z, Yan L, Lei M, Li X, Song Q, Shi B, Gu W, Li Z. Pan C, et al. Among authors: liu j, liu z, liu y, liu x. Zhonghua Nei Ke Za Zhi. 2015 Nov;54(11):949-53. Zhonghua Nei Ke Za Zhi. 2015. PMID: 26759214 Clinical Trial. Chinese.
194,095 results
You have reached the last available page of results. Please see the User Guide for more information.